1. Home
  2. CYCC vs MATH Comparison

CYCC vs MATH Comparison

Compare CYCC & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • MATH
  • Stock Information
  • Founded
  • CYCC 1992
  • MATH 2015
  • Country
  • CYCC Malaysia
  • MATH Hong Kong
  • Employees
  • CYCC N/A
  • MATH N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • MATH Finance/Investors Services
  • Sector
  • CYCC Health Care
  • MATH Finance
  • Exchange
  • CYCC Nasdaq
  • MATH Nasdaq
  • Market Cap
  • CYCC 61.2M
  • MATH 60.8M
  • IPO Year
  • CYCC N/A
  • MATH N/A
  • Fundamental
  • Price
  • CYCC $1.63
  • MATH $3.22
  • Analyst Decision
  • CYCC
  • MATH
  • Analyst Count
  • CYCC 0
  • MATH 0
  • Target Price
  • CYCC N/A
  • MATH N/A
  • AVG Volume (30 Days)
  • CYCC 191.0K
  • MATH 193.2K
  • Earning Date
  • CYCC 05-15-2025
  • MATH 01-01-0001
  • Dividend Yield
  • CYCC 147.24%
  • MATH N/A
  • EPS Growth
  • CYCC N/A
  • MATH N/A
  • EPS
  • CYCC N/A
  • MATH 0.17
  • Revenue
  • CYCC $14,000.00
  • MATH $31,399,049.00
  • Revenue This Year
  • CYCC $137.21
  • MATH N/A
  • Revenue Next Year
  • CYCC N/A
  • MATH N/A
  • P/E Ratio
  • CYCC N/A
  • MATH $19.30
  • Revenue Growth
  • CYCC N/A
  • MATH 291.58
  • 52 Week Low
  • CYCC $1.36
  • MATH $0.80
  • 52 Week High
  • CYCC $49.34
  • MATH $3.23
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 32.89
  • MATH 74.97
  • Support Level
  • CYCC $1.36
  • MATH $2.79
  • Resistance Level
  • CYCC $1.94
  • MATH $3.08
  • Average True Range (ATR)
  • CYCC 0.43
  • MATH 0.33
  • MACD
  • CYCC -0.07
  • MATH 0.06
  • Stochastic Oscillator
  • CYCC 8.31
  • MATH 99.11

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

Share on Social Networks: